How Designer Microbes and the Organism Industry Will Reshape Our World
Many investors are captivated by the future of companies such as Tesla Motors and 3-D Systems -- and the potential creation of shareholder value on a scale that will be difficult to match. But are investors overlooking an even more promising industry with a brighter future?
3 Synthetic Biology Stocks That Can Help You Grow in 2014 (and Beyond)
Large-scale genome editing can create entirely new organisms, but it can also create a number of growth opportunities for your portfolio. Here's how Agilent Technologies, Intrexon, and Solazyme can keep your portfolio chugging along in 2014.
5 Unbelievable (but Real) Technologies Made Possible by Synthetic Biology
The synthetic biology industry has erupted in recent years. The technological breakthroughs can touch numerous industries, from health care to marijuana production.
5 of Last Week's Biggest Winners
These five stocks posted double-digit percentage gains this past week.
This Engineered Salmon Could Double World Production: Should You Fear Frankenfish?
An engineered species of Atlantic salmon could double world aquaculture production, which stands at 230,000 metric tons per year, while offering substantial environmental benefits. What would it mean for consumers if Intrexon and AquaBounty Technologies gain regulatory approval from the U.S. Food and Drug Administration in 2014? A regulatory nod could notch a big win for synthetic biology in addition to pioneering technologies from Amyris and Solazyme.
Roundtable: What Could Be 2014's Twitter?
Twitter was one of the biggest investing stories of 2013. Which company will dominate 2014? Our top analysts share their thoughts, including looks at Intrexon and SolarCity.
Why Halozyme Therapeutics Inc. Shares Jumped
Halozyme shares jump after announcing who will become its next CEO.